Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Summary

The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate \[OTFC\]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clock (ATC) opioid therapy.

Timeline

Start

2006-10

Primary completion

2006-12

Completion

—

Drugs

Indications